Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2016
Pharmacy Choice - News - Front Page Healthcare News - May 30, 2016

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/29/16 - Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex , a novel, broad-spectrum, topical antibiotic peptide, announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Ph
5/29/16 - H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of the Eisai Group, announced that the U.S. Food and Drug Administration accepted the company's Investigational New Drug application
5/29/16 - IDELVION CSL Behring's Innovative Therapy for Hemophilia B Patients Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA CSL Behring announced it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration for IDELVION. The FDA grants marketing exclusivity for innovative, first-to-market orphan drugs, such as IDELVION. IDELVION was approved by the FDA in March
5/29/16 - Reynolds executives express optimism, rather than gloom, with new FDA rules
During a London presentation, the executives, led by chief executive Susan Cameron, discussed the company's reaction to the FDA regulations that were finalized May 5. It's clear Reynolds- at least for now- is not interested in taking legal action against the FDA for the new rules as have as least two small vaping companies. Cameron said she was ple
5/29/16 - Statewide Medicaid Comprehensive Hemophilia Management (MCHM) Program [TendersInfo (India)]
Tenders are invited for Statewide Medicaid Comprehensive Hemophilia Management Program Purpose: The Agency is seeking a qualified Vendor or Vendors to develop, implement, and provide a disease management program for a Statewide MCHM program in the State of Florida. The Vendor shall demonstrate specific knowledge and expertise in hemophilia disease.
5/29/16 - Supply of medical devices for the needs of state fiscal health institutions of the tver region tver regional clinical tb dispensary [TendersInfo (India)]
Request for quotations: supply of medical devices for the needs of state fiscal health institutions of the tver region tver regional clinical tb dispensary The initial contract price: 94520.00 russian rouble Requirements for participants: not installed restricting participation in the definition of the supplier, established in accordance with the..
5/28/16 - AbbVie, Biogen: FDA Approves Once-Monthly ZINBRYTA For Multiple Sclerosis
WESTON- AbbVie, a research-based biopharmaceutical company, and Biogen late Friday announced that the U.S. Food and Drug Administration or FDA approved ZINBRYTA, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis or RMS. The FDA approval of ZINBRYTA is primarily based on results from two clinical
5/28/16 - Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA? (Daclizumab) for Multiple Sclerosis
CAMBRIDGE, Mass.& NORTH CHICAGO, Ill. The U.S. Food and Drug Administration approved ZINBRYTA TM, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis, Biogen and AbbVie announced today. Clinical data showed ZINBRYTA significantly reduced relapses and brain lesions for up to three years compare
5/28/16 - FDA Grants Accelerated Approval to Ocaliva? (Obeticholic Acid) for the Treatment of Patients with PBC
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration has granted accelerated approval to Ocaliva for the treatment of primary biliary cholangitis, previously know
5/28/16 - India : Cipla wins regulatory approval to sell its version of Truvada [TendersInfo (India)]
Drugmaker Cipla has won regulatory approval in India for the sale of its version of Truvada as a preventive that healthy people can use to lower their risk of getting HIV. Commonly called PrEP in the healthcare industry, Truvada, sold by US drug manufacturer Gilead, is the sole medicine approved worldwide as a preventive in handling HIV. The recent
5/28/16 - The FDA rejects application for the registration og The NGAL TestTM
The Food and Drug Administration has informed BioPorto A/S that the registration application for The NGAL Test? has been rejected on the grounds that the submission does not provide adequate clinical and analytical data to support a reasonable assurance of approval of the device.. FDA's response means that BioPorto cannot begin commercialization
5/28/16 - United Kingdom : AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for... [TendersInfo (India)]
United Kingdom: AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate for oral suspension for treatment of hyperkalaemia. AstraZeneca today announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for sodium zirconium cyclosilicate, the...
5/28/16 - United States : FDA approves first buprenorphine implant for treatment of opioid dependence [TendersInfo (India)]
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. An independent FDA advisory committee supported the approval of Probuphine in a meeting held earlier this year. Expanding the use and availability of medication-assisted treatment options like...
5/28/16 - United States : FDA approves new diagnostic imaging agent to detect recurrent prostate cancer [TendersInfo (India)]
The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Prostate cancer is the second leading cause of death from cancer in U.S. men. Imaging tests are not able to determine the location of the recurrent prostate cancer when the PSA is at very low levels, said Libero Marzella, M.D., Ph.D., director
5/28/16 - United States : Oasmia Pharma to identify globa marketing, distribution, and development partners [TendersInfo (India)]
Oasmia Pharmaceutical AB has announced its plan to identify global marketing, distribution, and development partners to ease entry into several key markets following expected but pending approval from regulatory bodies in Europe, the United States, and other regions across the world. The Company sees this step as a key objective following its recen
5/27/16 - A better way to diagnose and manage neuroendocrine tumors
By a News Reporter-Staff News Editor at Health& Medicine Week Reston, Va.- A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors, and could significan
5/27/16 - AAMI Cautions FDA About Unintended Consequences of Regulating Medical Device Repair
Asserting its role as "a neutral organization that highly values its...'honest broker reputation,' " AAMI has submitted comments to the FDA concerning medical device repair and refurbishment in advance of the agency's June 3 deadline. The 18-page letter, followed by nearly 40 more pages of attachments, notes the dangers of silo-based thinking and a
5/27/16 - AbbVie's HUMIRA (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]
AbbVie, a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids or in
5/27/16 - Aim Health Welcomes New West Linn Family Doctor, Dr. Kathryn Kolonic [Daily Tribune (Bahrain)]
-AIM Health, a new hybrid primary care clinic that offers both a concierge and traditional patient model in West Linn, Oregon, announces the addition of a new family practitioner, Dr. Kathryn Kolonic, formerly at Providence Health in Canby. Dr. Kolonic will began accepting new patients at AIM Health starting May 23, 2016.
5/27/16 - Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
5/27/16 - AstraZeneca Gets CRL From U.S. FDA For ZS-9
LONDON- AstraZeneca said that the US Food and Drug Administration has issued a Complete Response Letter or CRL regarding the New Drug Application or NDA for sodium zirconium cyclosilicate, the investigational medicine being developed for the treatment of hyperkalaemia by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. AstraZeneca and ZS Pharma
5/27/16 - ASTRAZENECA RECEIVES COMPLETE RESPONSE LETTER FROM US FDA FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR ORAL SUSPENSION FOR TREATMENT OF HYPERKALAEMIA
AstraZeneca today announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for sodium zirconium cyclosilicate, the investigational medicine being developed for the treatment of hyperkalaemia by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. AstraZeneca and ZS Pharma are...
5/27/16 - Bankruptcy judge sets hearing on Stokes County proposal to acquire hospital
A federal Bankruptcy Court judge has set a hearing for June 24 to determine whether to allow Stokes County to take over the operations- including 200- plus employees- of Pioneer Community Hospital of Stokes County. The bankruptcy court in the Southern District of Mississippi is handling Pioneer's Chapter 11 filing of March 31. Health care systems n
5/27/16 - Coherus BioSciences Advances Differentiated IP Strategy for Humira Market Access [National News Agency (Lebanon)]
-Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus..
5/27/16 - Cordata and PatientBond Partner to Improve Specialty Care Coordination with Personalized Communications [Khaleej Times (United Arab Emirates)]
Cordata Healthcare Innovations today announced a partnership with PatientBond, LLC. This partnership benefits our hospital and health system clients in multiple ways, from focusing care coordination resources on the interactions that matter most, to helping patients overcome barriers to care and stick to their treatment plans, said Gary Winzenread,
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415